MedPath

A study to compare how easily patients with breathing conditions (asthma, chronic obstructive pulmonary disease (COPD) and asthma COPD overlap syndrome) can use two different types of inhaler.

Phase 1
Active, not recruiting
Conditions
Asthma, Asthma-COPD Overlap Syndrome (ACOS) and Chronic Obstructive Pulmonary Disease.
MedDRA version: 19.1 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 19.1 Level: LLT Classification code 10003555 Term: Asthma bronchial System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 19.1 Level: LLT Classification code 10009028 Term: Chronic obstructive asthma (with obstructive pulmonary disease) System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Registration Number
EUCTR2014-004564-38-GB
Lead Sponsor
Mundipharma Research Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
Not specified
Target Recruitment
369
Inclusion Criteria

1. Written informed consent/assent.
2. Male and female subject’s =18 years old.
3. Female subjects less than one year post-menopausal must have a negative urine pregnancy test prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), true sexual abstinence, where this is in line with the preferred and usual lifestyle of the subject, or vasectomized partner. Note: Periodic abstinence (calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for duration of study, and withdrawal are not acceptable methods of contraception).
4. Documented history of asthma, ACOS or COPD for = 6 months prior to Visit 1.
5. Subjects currently using Seretide® Accuhaler®/ Viani® Diskus® (100/50 bid, 250/50 bid or 500/50 bid) for at least 3 months prior to Visit 1 and naïve to Turbohaler® (whether containing SABA, ICS or ICS-LABA) and K-haler.
6. Subject currently uses a specific reliever(s) device(s) for at least 3 months prior to Visit 1.
7. Can perform spirometry adequately.
8. Willing and able to attend all study visits.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 221
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 147

Exclusion Criteria

1. Any severe chronic respiratory disease other than asthma, ACOS or COPD.
2. Subjects that have previously used Turbohaler® (whether containing SABA, ICS or ICS-LABA) and/or the K-haler®.
3. Subjects currently using Seretide® Accuhaler®/Viani® Diskus® 500/50 bid in whom the Investigator considers it a risk to patient safety to switch to Symbicort® 400/12 bid or fluticasone/formoterol 250/10 bid.
4. Subjects currently using any fixed dose ICS/LABA other than Seretide® Accuhaler®.
5. Near fatal or life-threatening (including intubation) asthma, ACOS or COPD within one year of Visit 1.
6. Use of systemic (injectable or oral) corticosteroid medication within 4 weeks of Visit 1.
7. Evidence of a clinically unstable disease that, in the Investigator’s opinion, may confound between period comparisons or would put the Subject at risk through study participation.
8. A clinically significant upper or lower respiratory infection within 4 weeks prior to Visit 1.
9. Known or suspected sensitivity to study drug or excipients.
10. Current participation in a clinical study.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath